New antibody drug aims to shrink Hard-to-Treat tumors

NCT ID NCT07582822

First seen May 15, 2026 · Last updated May 15, 2026

Summary

This early-phase study tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a bispecific antibody designed to target two cancer-related proteins (EGFR and cMET). The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hunan Cancer Hospital

    Changsha, Hunan, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Nanjing Tianyinshan Hospital

    Nanjing, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanghai East Hospital

    Shanghai, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Pulmonary Hospital Affiliated to Tongji University

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yibin Second People's Hospital

    Yibin, Sichuan, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.